Johnson & Johnson
Jul 14, 2009

Johnson & Johnson Reports 2009 Second-Quarter Results:

--Sales of $15.2 Billion Decreased 7.4% Versus 2008 Second Quarter --EPS of $1.15 Decreased 2.5%* Versus 2008 Second Quarter, Excluding 2008 Special Items

NEW BRUNSWICK, N.J., July 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.2 billion for the second quarter of 2009, a decrease of 7.4% as compared to the second quarter of 2008. Operational results declined 1.4% and the negative impact of currency was 6.0%. Domestic sales declined 6.7%, while international sales declined 8.0%, reflecting operational growth of 3.9% and a negative currency impact of 11.9%.

Net earnings and diluted earnings per share for the second quarter of 2009 were $3.2 billion and $1.15, respectively. The second quarter of 2008 included an after-tax in-process research and development charge of $40 million. Excluding this charge, net earnings for the quarter and diluted earnings per share represent decreases of 4.7% and 2.5%, respectively, as compared to the same period in 2008.* The Company confirmed its earnings guidance for full-year 2009 of $4.45 - $4.55 per share, which excludes the impact of special items.

"I am proud of the accomplishments of our people in continuing to deliver very solid operational results in light of the significant impacts of patent expirations and the economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "Our investments through internal research and development, strategic partnerships and acquisitions have allowed us to build what is considered by many to be one of the best pipelines in our industry. We will continue to invest in our portfolio of innovative products to meet the needs of patients and consumers around the world."

Worldwide Consumer sales of $3.9 billion for the second quarter represented a decrease of 4.5% versus the prior year with an increase of 3.1% operationally and a negative impact from currency of 7.6%. Domestic sales increased 0.8%; while international sales decreased 8.4%, which reflected an operational increase of 4.7% and a negative currency impact of 13.1%.

LISTERINE® antiseptic mouthrinse and the skin care lines of NEUTROGENA® and AVEENO® contributed to operational sales growth during the quarter. Other growth drivers were sales from the recently completed acquisition of the French company Vania Expansion SNC.

Worldwide Pharmaceutical sales of $5.5 billion for the second quarter represented a decrease versus the prior year of 13.3% with an operational decline of 8.5% and a negative impact from currency of 4.8%. Domestic sales decreased 16.4%; while international sales decreased 8.7%, which reflected an operational increase of 3.3% and a negative currency impact of 12.0%.

REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and CONCERTA® (methylphenidate HCI), a treatment for attention deficit hyperactivity disorder, had strong operational sales performance during the quarter. Sales results of TOPAMAX® (topiramate), an anti-epileptic, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate, active psoriatic arthritis with or without methotrexate, and active ankylosing spondylitis. The FDA also approved the Supplemental New Drug Applications (sNDAs) for the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment as both monotherapy and adjunctive therapy to lithium or valproate in the maintenance treatment of Bipolar I Disorder. The Drug Enforcement Administration (DEA) issued their final ruling and placed NUCYNTA (tapentadol) CII immediate release tablets for the relief of moderate to severe acute pain in patients 18 years of age or older into Schedule II of the Controlled Substances Act. The product is now available to patients.

The Company also announced a definitive agreement to acquire Cougar Biotechnology, a development stage biopharmaceutical company with a specific focus on oncology, for approximately $1.0 billion in a cash tender offer. On July 9, 2009, the acquisition of Cougar Biotechnology was completed. On July 2, 2009, the Company announced a definitive agreement with Elan Corporation, plc. whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program and will invest $1 billion in Elan newly issued American Depositary Receipts (ADRs).

Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the second quarter represented a decrease of 3.1% versus the prior year with an operational increase of 2.9% and a negative currency impact of 6.0%. Domestic sales increased 1.9%; while international sales decreased 7.2%, which reflected an operational increase of 3.7% and a negative currency impact of 10.9%.

Primary contributors to the operational growth included Ethicon's surgical care products; Ortho-Clinical Diagnostics' professional products; Ethicon Endo-Surgery's minimally invasive products; and DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses. Also contributing to growth were sales of products acquired as part of the completed acquisition of Mentor Corporation, a leading supplier of medical products for the global aesthetic market. This growth was partially offset by lower sales in the Cordis franchise, reflecting new competitive entries in the drug-eluting stent market as well as the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

About Johnson & Johnson

Caring for the world, one person at a time. . .inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax in-process research and development charges, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at www.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data

    (Unaudited; Dollars in Millions)             SECOND QUARTER
    -------------------------------              --------------
                                                        Percent Change
                                                        --------------
                                     2009   2008    Total  Operations Currency
    ---------------------            ----   ----    -----  ---------- --------
    Sales to customers by
    segment of business

    Consumer
        U.S.                       $1,708  1,694      0.8%     0.8         -
        International               2,146  2,342     (8.4)     4.7     (13.1)
    -----------------               -----  -----     ----      ---     -----
                                    3,854  4,036     (4.5)     3.1      (7.6)
                                    -----  -----     ----      ---      ----

    Pharmaceutical
        U.S.                        3,172  3,793    (16.4)   (16.4)        -
        International               2,326  2,547     (8.7)     3.3     (12.0)
    -----------------               -----  -----     ----      ---     -----
                                    5,498  6,340    (13.3)    (8.5)     (4.8)
                                    -----  -----    -----     ----      ----

    Med Devices & Diagnostics
        U.S.                        2,776  2,723      1.9      1.9         -
        International               3,111  3,351     (7.2)     3.7     (10.9)
    -----------------               -----  -----     ----      ---     -----
                                    5,887  6,074     (3.1)     2.9      (6.0)
                                    -----  -----     ----      ---      ----

    U.S.                            7,656  8,210     (6.7)    (6.7)        -
    International                   7,583  8,240     (8.0)     3.9     (11.9)
    -------------                   -----  -----     ----      ---     -----
    Worldwide                     $15,239 16,450     (7.4)%   (1.4)     (6.0)
    ---------                     ------- ------     ----     ----      ----


    (Unaudited; Dollars in Millions)               SIX MONTHS
    -------------------------------                ----------
                                                        Percent Change
                                                        --------------
                                     2009   2008    Total Operations  Currency
    ---------------------            ----   ----    ----- ----------  --------
    Sales to customers by
    segment of business

    Consumer
        U.S.                       $3,434  3,513     (2.2)%   (2.2)        -
        International               4,131  4,587     (9.9)     3.6     (13.5)
    -----------------               -----  -----     ----      ---     -----
                                    7,565  8,100     (6.6)     1.0      (7.6)
                                    -----  -----     ----      ---      ----

    Pharmaceutical
        U.S.                        6,846  7,863    (12.9)   (12.9)        -
        International               4,432  4,906     (9.7)     3.1     (12.8)
    -----------------               -----  -----     ----      ---     -----
                                   11,278 12,769    (11.7)    (6.8)     (4.9)
                                   ------ ------    -----     ----      ----

    Med Devices & Diagnostics
        U.S.                        5,428  5,311      2.2      2.2         -
        International               5,994  6,464     (7.3)     3.6     (10.9)
    -----------------               -----  -----     ----      ---     -----
                                   11,422 11,775     (3.0)     3.0      (6.0)
                                   ------ ------     ----      ---      ----

    U.S.                           15,708 16,687     (5.9)    (5.9)        -
    International                  14,557 15,957     (8.8)     3.5     (12.3)
    -------------                  ------ ------     ----      ---     -----
    Worldwide                     $30,265 32,644     (7.3)%   (1.3)     (6.0)
    ---------                     ------- ------     ----     ----      ----


    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data


    (Unaudited; Dollars in Millions)            SECOND QUARTER
    --------------------------------            --------------
                                                       Percent Change
                                                       --------------
                                    2009   2008    Total  Operations  Currency
                                    ----   ----    -----  ----------  --------
    Sales to customers by
    geographic area
    U.S.                          $7,656  8,210     (6.7)%    (6.7)        -
    ----                          ------  -----     ----      ----       ---

    Europe                         3,972  4,547    (12.6)      1.8     (14.4)
    Western Hemisphere
     excluding U.S.                1,215  1,280     (5.1)     11.7     (16.8)
    Asia-Pacific, Africa           2,396  2,413     (0.7)      3.7      (4.4)
    --------------------           -----  -----     ----       ---      ----
    International                  7,583  8,240     (8.0)      3.9     (11.9)
    -------------                  -----  -----     ----       ---     -----

    Worldwide                    $15,239 16,450     (7.4)%    (1.4)     (6.0)
    ---------                    ------- ------     ----      ----      ----


    (Unaudited; Dollars in Millions)              SIX MONTHS
    -------------------------------               ----------
                                                       Percent Change
                                                       --------------
                                    2009   2008    Total  Operations  Currency
                                    ----   ----    -----  ----------  --------
    Sales to customers by
    geographic area
    U.S.                         $15,708 16,687     (5.9)%    (5.9)        -
    ---------------------        ------- ------     ----      ----       ---

    Europe                         7,643  8,855    (13.7)      0.8     (14.5)
    Western Hemisphere
     excluding U.S.                2,277  2,525     (9.8)      8.2     (18.0)
    Asia-Pacific, Africa           4,637  4,577      1.3       5.9      (4.6)
    --------------------           -----  -----      ---       ---      ----
    International                 14,557 15,957     (8.8)      3.5     (12.3)
    -------------                 ------ ------     ----       ---     -----

    Worldwide                    $30,265 32,644     (7.3)%    (1.3)     (6.0)
    ---------                    ------- ------     ----      ----      ----


    Johnson & Johnson and Subsidiaries
    -----------------------------------
    Condensed Consolidated Statement of Earnings

    (Unaudited; in Millions Except
     Per Share Figures)                     SECOND QUARTER
    ------------------------------          --------------

                                2009                 2008            Percent
                          ----------------    ------------------
                                   Percent               Percent    Increase
                          Amount  to Sales     Amount   to Sales   (Decrease)
    ------------------    ------  --------     ------   --------   ---------
    Sales to customers   $15,239     100.0    $16,450      100.0        (7.4)
    ------------------   -------     -----    -------      -----        ----
    Cost of products
     sold                  4,450      29.2      4,751       28.9        (6.3)
    Selling, marketing
     and administrative
     expenses              4,797      31.5      5,507       33.5       (12.9)
    Research &
     development expense   1,638      10.7      1,896       11.5       (13.6)
    In-process research
     & development             -         -         40        0.2
    Interest (income)
     expense, net             85       0.6         16        0.1
    Other (income)
     expense, net              6         -       (135)      (0.8)
    --------------           ---       ---       ----       ----        ----
    Earnings before
     provision for taxes
     on income             4,263      28.0      4,375       26.6        (2.6)
    Provision for taxes
     on income             1,055       6.9      1,048        6.4         0.7
    -------------------    -----       ---      -----        ---         ---
    Net earnings          $3,208      21.1     $3,327       20.2        (3.6)
    ------------          ------      ----     ------       ----        ----


    Net earnings per
     share  (Diluted)      $1.15                $1.17                   (1.7)

    Average shares
     outstanding
     (Diluted)           2,782.0              2,844.8

    Effective tax rate      24.7%                24.0%

    --------------------
    Adjusted earnings before
     provision for taxes and
     net earnings
      Earnings before
       provision for taxes
       on income          $4,263      28.0     $4,415 (1)   26.8        (3.4)
      Net earnings        $3,208      21.1     $3,367 (1)   20.5        (4.7)
      Net earnings per
       share (Diluted)     $1.15                $1.18 (1)               (2.5)
      Effective tax
       rate                 24.7%                23.7%


    (1) The difference between as reported and as adjusted earnings before
        provision for taxes on income and net earnings and net earnings per
        share (diluted) is IPR&D of $40 million with no tax benefit and $0.01
        per share, respectively.


    Johnson & Johnson and Subsidiaries
    -----------------------------------
    Condensed Consolidated Statement of Earnings


    (Unaudited; in Millions Except
     Per Share Figures)                      SIX MONTHS
    ------------------------------           ----------

                              2009                   2008           Percent
                        ----------------     ------------------
                                 Percent                Percent    Increase
                        Amount  to Sales      Amount   to Sales   (Decrease)
    ------------------  ------  --------      ------   --------  ------------
    Sales to customers $30,265     100.0     $32,644      100.0       (7.3)
    ------------------ -------     -----     -------      -----       ----
    Cost of products
     sold                8,701      28.7       9,365       28.7       (7.1)
    Selling,
     marketing and
     administrative
     expenses            9,405      31.1      10,630       32.6      (11.5)
    Research &
     development
     expense             3,156      10.4       3,608       11.1      (12.5)
    In-process
     research &
     development             -         -          40        0.1
    Interest (income)
     expense, net          166       0.6          32        0.1
    Other (income)
     expense, net          (69)     (0.2)       (153)      (0.5)
    --------------         ---      ----        ----       ----       ----
    Earnings before
     provision for
     taxes on income     8,906      29.4       9,122       27.9       (2.4)
    Provision for
     taxes on income     2,191       7.2       2,197        6.7       (0.3)
    ----------------     -----       ---       -----        ---       ----
    Net earnings        $6,715      22.2      $6,925       21.2       (3.0)
    ------------        ------      ----      ------       ----       ----


    Net earnings per
     share  (Diluted)    $2.41                 $2.43                  (0.8)

    Average shares
     outstanding
     (Diluted)         2,785.5               2,856.1

    Effective tax rate    24.6%                 24.1%

    ------------------
    Adjusted earnings before
     provision for taxes
     and net earnings
      Earnings before
       provision for
       taxes on income  $8,906      29.4      $9,162 (1)   28.1       (2.8)
      Net earnings      $6,715      22.2      $6,965 (1)   21.3       (3.6)
      Net earnings per
       share  (Diluted)  $2.41                 $2.44 (1)              (1.2)
      Effective tax
       rate               24.6%                 24.0%

    (1) The difference between as reported and as adjusted earnings before
        provision for taxes on income and net earnings and net earnings per
        share (diluted) is IPR&D of $40 million with no tax benefit and $0.01
        per share, respectively.


                   REPORTED SALES vs. PRIOR PERIOD ($MM)
                   -------------------------------------

                                            SECOND QUARTER
                             --------------------------------------------
                                                      % Change
                                         ---------------------------------
                             2009   2008 Reported Operational (1) Currency
                             ----   ---- -------- --------------- --------
    CONSUMER SEGMENT (2)
    --------------------

    SKIN CARE
    ---------
    US                        411    379     8.4%        8.4%           -
    Intl                      422    460    -8.3%        3.8%       -12.1%
    WW                        833    839    -0.7%        5.9%        -6.6%

    BABY CARE
    ---------
    US                        104    111    -6.3%       -6.3%           -
    Intl                      404    461   -12.4%       -1.2%       -11.2%
    WW                        508    572   -11.2%       -2.2%        -9.0%

    ORAL CARE
    ---------
    US                        174    185    -5.9%       -5.9%           -
    Intl                      212    223    -4.9%        9.5%       -14.4%
    WW                        386    408    -5.4%        2.4%        -7.8%

    OTC/NUTRITIONALS
    ----------------
    US                        679    679       -            -           -
    Intl                      631    726   -13.1%        0.6%       -13.7%
    WW                      1,310  1,405    -6.8%        0.3%        -7.1%

    WOMEN'S HEALTH
    --------------
    US                        152    158    -3.8%       -3.8%           -
    Intl                      329    346    -4.9%        8.8%       -13.7%
    WW                        481    504    -4.6%        4.8%        -9.4%

    WOUND CARE / OTHER
    ------------------
    US                        188    182     3.3%        3.3%           -
    Intl                      148    126    17.5%       33.6%       -16.1%
    WW                        336    308     9.1%       15.7%        -6.6%

    TOTAL CONSUMER
    --------------
    US                      1,708  1,694     0.8%        0.8%           -
    Intl                    2,146  2,342    -8.4%        4.7%       -13.1%
    WW                      3,854  4,036    -4.5%        3.1%        -7.6%


    * See footnotes below


    PHARMACEUTICAL SEGMENT (2)
    --------------------------

    ACIPHEX/PARIET
    --------------
    US                        128    153   -16.3%      -16.3%         -
    Intl                      132    172   -23.3%      -10.6%       -12.7%
    WW                        260    325   -20.0%      -13.3%        -6.7%

    CONCERTA
    --------
    US                        233    208    12.0%       12.0%         -
    Intl                       84     71    18.3%       38.0%       -19.7%
    WW                        317    279    13.6%       18.7%        -5.1%

    DURAGESIC/FENTANYL TRANSDERMAL
    ------------------------------
    US                         50     70   -28.6%      -28.6%         -
    Intl                      168    202   -16.8%       -6.5%       -10.3%
    WW                        218    272   -19.9%      -12.3%        -7.6%

    LEVAQUIN/FLOXIN
    ---------------
    US                        343    330     3.9%        3.9%         -
    Intl                       19     21    -9.5%        7.3%       -16.8%
    WW                        362    351     3.1%        4.1%        -1.0%

    PROCRIT/EPREX
    --------------
    US                        330    346    -4.6%       -4.6%         -
    Intl                      247    306   -19.3%       -7.6%       -11.7%
    WW                        577    652   -11.5%       -6.0%        -5.5%

    RAZADYNE/REMINYL
    ----------------
    US                         16     42   -61.9%      -61.9%         -
    Intl                       91    110   -17.3%       -4.2%       -13.1%
    WW                        107    152   -29.6%      -20.1%        -9.5%

    REMICADE
    --------
    US                        771    684    12.7%       12.7%         -
    US Exports (4)            327    200    63.5%       63.5%         -
    Intl                        4      2   100.0%       96.2%         3.8%
    WW                      1,102    886    24.4%       24.4%         -

    RISPERDAL/RISPERIDONE
    ---------------------
    US                         70    492   -85.8%      -85.8%         -
    Intl                      169    220   -23.2%      -17.9%        -5.3%
    WW                        239    712   -66.4%      -64.8%        -1.6%

    RISPERDAL CONSTA
    ----------------
    US                        131    120     9.2%        9.2%           -
    Intl                      217    223    -2.7%       13.7%       -16.4%
    WW                        348    343     1.5%       12.1%       -10.6%

    TOPAMAX
    -------
    US                         75    548   -86.3%      -86.3%         -
    Intl                      107    129   -17.1%       -2.9%       -14.2%
    WW                        182    677   -73.1%      -70.4%        -2.7%

    VELCADE
    -------
    US                        -        1  -100.0%     -100.0%         -
    Intl                      229    204    12.3%       26.9%       -14.6%
    WW                        229    205    11.7%       26.2%       -14.5%

    OTHER
    -----
    US                        698    599    16.5%       16.5%         -
    Intl                      859    887    -3.2%       11.3%       -14.5%
    WW                      1,557  1,486     4.8%       13.5%        -8.7%

    TOTAL PHARMACEUTICAL
    --------------------
    US                      3,172  3,793   -16.4%      -16.4%         -
    Intl                    2,326  2,547    -8.7%        3.3%       -12.0%
    WW                      5,498  6,340   -13.3%       -8.5%        -4.8%


    MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
    -------------------------------------

    PREZISTA
    US                         65     43    51.2%       51.2%         -
    Intl                       75     45    66.7%       90.0%       -23.3%
    WW                        140     88    59.1%       71.0%       -11.9%

    INVEGA
    US                         67     62     8.1%        8.1%         -
    Intl                       32     14   128.6%      163.7%       -35.1%
    WW                         99     76    30.3%       36.6%        -6.3%

    * See footnotes below


    MEDICAL DEVICES AND DIAGNOSTICS (2)(3)
    --------------------------------------

    CORDIS (6)
    ----------
    US                        252    328   -23.2%      -23.2%         -
    Intl                      422    485   -13.0%       -5.5%        -7.5%
    WW                        674    813   -17.1%      -12.6%        -4.5%

    DEPUY
    -----
    US                        762    722     5.5%        5.5%         -
    Intl                      561    606    -7.4%        6.5%       -13.9%
    WW                      1,323  1,328    -0.4%        6.0%        -6.4%

    DIABETES CARE
    -------------
    US                        306    338    -9.5%       -9.5%         -
    Intl                      304    336    -9.5%        2.2%       -11.7%
    WW                        610    674    -9.5%       -3.7%        -5.8%

    ETHICON
    -------
    US                        452    374    20.9%       20.9%         -
    Intl                      589    646    -8.8%        3.2%       -12.0%
    WW                      1,041  1,020     2.1%        9.7%        -7.6%

    ETHICON ENDO-SURGERY
    --------------------
    US                        489    484     1.0%        1.0%         -
    Intl                      626    640    -2.2%       10.7%       -12.9%
    WW                      1,115  1,124    -0.8%        6.3%        -7.1%

    ORTHO-CLINICAL DIAGNOSTICS
    --------------------------
    US                        284    250    13.6%       13.6%         -
    Intl                      210    226    -7.1%        4.2%       -11.3%
    WW                        494    476     3.8%        9.2%        -5.4%

    VISION CARE
    -----------
    US                        231    227     1.8%        1.8%         -
    Intl                      399    412    -3.2%        2.0%        -5.2%
    WW                        630    639    -1.4%        1.9%        -3.3%

    TOTAL MEDICAL DEVICES AND DIAGNOSTICS
    -------------------------------------
    US                      2,776  2,723     1.9%        1.9%         -
    Intl                    3,111  3,351    -7.2%        3.7%       -10.9%
    WW                      5,887  6,074    -3.1%        2.9%        -6.0%


    1) Operational growth excludes the effect of currency
    2) Select areas (unaudited)
    3) Prior year amounts have been reclassified to conform with current
       presentation
    4) For external purposes, reported as U.S. sales
    5) Included in Other
    6) Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and
       $234 million Domestic, International and Worldwide respectively
       Includes sales of Drug-Eluting Stents for Q2 2008 of $167, $227 and
       $394 million Domestic, International and Worldwide respectively
       Includes sales of Drug-Eluting Stents for June YTD 2009 of $136,
       $349 and $485 million Domestic, International and Worldwide
       respectively
       Includes sales of Drug-Eluting Stents for June YTD 2008 of $336,
       $458 and $794 million Domestic, International and Worldwide
       respectively



                                                 SIX MONTHS
                               --------------------------------------------
                                                      % Change
                                          ---------------------------------
                               2009  2008 Reported Operational (1) Currency
                               ----  ---- -------- --------------- --------
    CONSUMER SEGMENT (2)
    --------------------

    SKIN CARE
    ---------
    US                         834     761     9.6%     9.6%          -
    Intl                       841     918    -8.4%     4.6%        -13.0%
    WW                       1,675   1,679    -0.2%     6.9%         -7.1%

    BABY CARE
    ---------
    US                         206     226    -8.8%    -8.8%          -
    Intl                       791     879   -10.0%     1.5%        -11.5%
    WW                         997   1,105    -9.8%    -0.7%         -9.1%

    ORAL CARE
    ---------
    US                         362     384    -5.7%    -5.7%          -
    Intl                       389     410    -5.1%    10.4%        -15.5%
    WW                         751     794    -5.4%     2.6%         -8.0%

    OTC/NUTRITIONALS
    ----------------
    US                       1,405   1,521    -7.6%    -7.6%          -
    Intl                     1,253   1,478   -15.2%    -0.9%        -14.3%
    WW                       2,658   2,999   -11.4%    -4.3%         -7.1%

    WOMEN'S HEALTH
    --------------
    US                         301     306    -1.6%    -1.6%          -
    Intl                       603     659    -8.5%     4.9%        -13.4%
    WW                         904     965    -6.3%     2.8%         -9.1%

    WOUND CARE / OTHER
    ------------------
    US                         326     315     3.5%     3.5%          -
    Intl                       254     243     4.5%    19.4%        -14.9%
    WW                         580     558     3.9%    10.4%         -6.5%

    TOTAL CONSUMER
    --------------
    US                       3,434   3,513    -2.2%    -2.2%          -
    Intl                     4,131   4,587    -9.9%     3.6%        -13.5%
    WW                       7,565   8,100    -6.6%     1.0%         -7.6%

    * See footnotes below


    PHARMACEUTICAL SEGMENT (2)
    --------------------------

    ACIPHEX/PARIET
    --------------
    US                         266     269    -1.1%    -1.1%          -
    Intl                       257     333   -22.8%    -9.5%        -13.3%
    WW                         523     602   -13.1%    -5.7%         -7.4%

    CONCERTA
    --------
    US                         502     432    16.2%    16.2%          -
    Intl                       159     137    16.1%    37.6%        -21.5%
    WW                         661     569    16.2%    21.4%         -5.2%

    DURAGESIC/FENTANYL TRANSDERMAL
    ------------------------------
    US                         125     145   -13.8%   -13.8%          -
    Intl                       324     360   -10.0%     1.8%        -11.8%
    WW                         449     505   -11.1%    -2.7%         -8.4%

    LEVAQUIN/FLOXIN
    ---------------
    US                         751     804    -6.6%    -6.6%          -
    Intl                        36      43   -16.3%     2.0%        -18.3%
    WW                         787     847    -7.1%    -6.2%         -0.9%

    PROCRIT/EXPREX
    --------------
    US                         651     680    -4.3%    -4.3%          -
    Intl                       476     601   -20.8%    -8.7%        -12.1%
    WW                       1,127   1,281   -12.0%    -6.3%         -5.7%

    RAZADYNE/REMINYL
    ----------------
    US                          29      92   -68.5%   -68.5%          -
    Intl                       179     209   -14.4%     0.2%        -14.6%
    WW                         208     301   -30.9%   -20.8%        -10.1%

    REMICADE
    --------
    US                       1,508   1,360    10.9%    10.9%          -
    US Exports (4)             613     520    17.9%    17.9%          -
    Intl                         9       4   125.0%   118.1%          6.9%
    WW                       2,130   1,884    13.1%    13.1%          -

    RISPERDAL/RISPERIDONE
    ---------------------
    US                         188   1,074   -82.5%   -82.5%          -
    Intl                       326     447   -27.1%   -21.3%         -5.8%
    WW                         514   1,521   -66.2%   -64.5%         -1.7%

    RISPERDAL CONSTA
    ----------------
    US                         257     221    16.3%    16.3%          -
    Intl                       416     431    -3.5%    13.8%        -17.3%
    WW                         673     652     3.2%    14.6%        -11.4%

    TOPAMAX
    -------
    US                         570   1,068   -46.6%   -46.6%          -
    Intl                       214     255   -16.1%    -1.4%        -14.7%
    WW                         784   1,323   -40.7%   -37.9%         -2.8%

    VELCADE
    -------
    US                          -        3  -100.0%  -100.0%          -
    Intl                       421     386     9.1%    24.5%        -15.4%
    WW                         421     389     8.2%    23.5%        -15.3%

    OTHER
    -----
    US                       1,386   1,195    16.0%    16.0%          -
    Intl                     1,615   1,700    -5.0%    10.4%        -15.4%
    WW                       3,001   2,895     3.7%    12.7%         -9.0%

    TOTAL PHARMACEUTICAL
    --------------------
    US                       6,846   7,863   -12.9%   -12.9%          -
    Intl                     4,432   4,906    -9.7%     3.1%        -12.8%
    WW                      11,278  12,769   -11.7%    -6.8%         -4.9%


    MAJOR NEW PHARMACEUTICAL PRODUCTS (5)
    -------------------------------------

    PREZISTA
    --------
    US                         137      75    82.7%    82.7%          -
    Intl                       125      87    43.7%    66.5%        -22.8%
    WW                         262     162    61.7%    73.9%        -12.2%

    INVEGA
    ------
    US                         133     119    11.8%    11.8%          -
    Intl                        57      23   147.8%   186.4%        -38.6%
    WW                         190     142    33.8%    39.9%         -6.1%

    * See footnotes below


    MEDICAL DEVICES AND DIAGNOSTICS (2)(3)
    --------------------------------------

    CORDIS (6)
    ----------
    US                         498     670   -25.7%   -25.7%          -
    Intl                       844     944   -10.6%    -3.6%         -7.0%
    WW                       1,342   1,614   -16.9%   -12.8%         -4.1%

    DEPUY
    -----
    US                       1,528   1,431     6.8%     6.8%          -
    Intl                     1,087   1,184    -8.2%     6.5%        -14.7%
    WW                       2,615   2,615     -        6.6%         -6.6%

    DIABETES CARE
    -------------
    US                         576     641   -10.1%   -10.1%          -
    Intl                       575     648   -11.3%     0.5%        -11.8%
    WW                       1,151   1,289   -10.7%    -4.8%         -5.9%

    ETHICON
    -------
    US                         857     715    19.9%    19.9%          -
    Intl                     1,137   1,250    -9.0%     3.5%        -12.5%
    WW                       1,994   1,965     1.5%     9.4%         -7.9%

    ETHICON ENDO-SURGERY
    --------------------
    US                         943     913     3.3%     3.3%          -
    Intl                     1,187   1,214    -2.2%    11.1%        -13.3%
    WW                       2,130   2,127     0.1%     7.3%         -7.2%

    ORTHO-CLINICAL DIAGNOSTICS
    --------------------------
    US                         561     488    15.0%    15.0%          -
    Intl                       400     431    -7.2%     3.8%        -11.0%
    WW                         961     919     4.6%     9.7%         -5.1%

    VISION CARE
    -----------
    US                         465     453     2.6%     2.6%          -
    Intl                       764     793    -3.7%     0.5%         -4.2%
    WW                       1,229   1,246    -1.4%     1.3%         -2.7%

    TOTAL MEDICAL DEVICES AND DIAGNOSTICS
    -------------------------------------
    US                       5,428   5,311     2.2%     2.2%          -
    Intl                     5,994   6,464    -7.3%     3.6%        -10.9%
    WW                      11,422  11,775    -3.0%     3.0%         -6.0%


    1) Operational growth excludes the effect of currency
    2) Select areas (unaudited)
    3) Prior year amounts have been reclassified to conform with current
       presentation
    4) For external purposes, reported as U.S. sales
    5) Included in Other
    6) Includes sales of Drug-Eluting Stents for Q2 2009 of $69, $165 and
       $234 million Domestic, International and Worldwide respectively
       Includes sales of Drug-Eluting Stents for Q2 2008 of $167, $227 and
       $394 million Domestic, International and Worldwide respectively
       Includes sales of Drug-Eluting Stents for June YTD 2009 of $136,
       $349 and $485 million Domestic, International and Worldwide
       respectively
       Includes sales of Drug-Eluting Stents for June YTD 2008 of $336,
       $458 and $794 million Domestic, International and Worldwide
       respectively




SOURCE Johnson & Johnson

 
http://www.jnj.com

Copyright © 2009 PR Newswire. All rights reserved